Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan’s Nagoya University Establish Bio Venture Company To Develop Arteriosclerosis Drugs

This article was originally published in PharmAsia News

Executive Summary

Nagoya City University established the venture company Hyks Laboratories to develop drugs to treat and prevent arteriosclerosis. Utilizing funds from the Japan Science and Technology Agency, the university's school of medicine has been focusing on research and development of a drug to increase blood's high-density lipoproteins count, Based on the research results, the company also plans to partner with pharmaceutical companies to conduct basic research on HDL functions. Cerebral vascular diseases account for one third of the total deaths in Japan and prevention and treatment have become a major topic for medical researchers and pharmaceutical companies. (Click here for more - Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel